Emergent Biosolutions Inc (EBS) 8.0 USD (-1.72%) | Healthcare New York Stock Exchange

Emergent Biosolutions Inc is a global company specializing in biopharmaceutical products to support immune defenses and public health emergencies.

biotechnology health

Comment

Performance & Momentum

6 Months 26.47 %

1 Year 27.12 %

3 Years 1.70 %

5 Years 86.79 %

Momentum

Unlock this indicator

Recent News

Emergent Biosolutions Inc

Emergent BioSolutions Q2 2025 Results Beat Estimates

10 months ago

Emergent BioSolutions reported Q2 2025 revenue of $140.9 million, surpassing forecasts by $21 million, while reducing its net loss by 96% year-over-year. This strong operational improvement explains the notable 10.36% share price increase, reflecting renewed investor confidence in the company’s financial outlook.

source: globenewswire.com • quarterly report, financial performance

Tower Research Capital boosts Emergent BioSolutions stake

1 year ago

Tower Research Capital LLC (TRC) significantly increased its stake in Emergent BioSolutions Inc. by purchasing 16,345 shares, marking a sharp 7,075.8% rise in the fourth quarter. The sizable investment may signal renewed confidence in Emergent BioSolutions' outlook, especially as the stock fell 7.48% today.

source: etfdailynews.com • share purchase

Strategic Analysis

Emergent BioSolutions is positioned as a niche biopharma player focused on health security, with expertise in vaccines and medical countermeasures against biological threats. Its business model is driven more by specialized and often contract-based needs than by a broad consumer market logic, making it a stock exposed to public and institutional order cycles.

Strengths

Differentiated positioning in critical products linked to health preparedness and biodefense
Recognized expertise in medical countermeasures, a segment with high regulatory barriers
Exposure to potentially recurring demand when health security priorities intensify

Weaknesses

Very poor long-term stock market performance, signaling structural fragility and limited market confidence
Dependence on contracts and budget dynamics that can make revenues irregular

Momentum

Current momentum appears improved but still fragile: the recent trend shows a rebound from a very depressed base, without erasing an underlying trend that remains unstable. For an investor, this points to a speculative stock driven more by operational or contract-related catalysts than by an already established durable uptrend.

Analysis performed 1 week ago